Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 2/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.35 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11081265 | 0.76 | SRD5A1 (0.35) | PTGIRPTGDRSRD5A1 | |
| SCHEMBL7401882 | 0.74 | SIGMAR1 (0.45) | SRD5A1NOTUMKDM4E | |
| SCHEMBL13074756 | 0.72 | AKR1C3 (0.39) | SRD5A1NOTUM | |
| SCHEMBL11083951 | 0.69 | ALDH1A1 (0.49) | PTGDR2KDM4E | |
| SCHEMBL5211828 | 0.69 | PTGIR (0.44) | PTGIRPTGDR | |
| SCHEMBL21823159 | 0.68 | SRD5A1 (0.38) | SRD5A1NOTUM | |
| SCHEMBL5211156 | 0.68 | CA12 (0.42) | PPARG | |
| SCHEMBL5212129 | 0.66 | PTGIR (0.42) | PTGIRPTGDRSMN1; SMN2 | |
| SCHEMBL3451418 | 0.66 | AKR1B1 (0.56) | — | |
| SCHEMBL14460080 | 0.65 | GSTP1 (0.42) | KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877779-B2 | Benzimidazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2128154-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | ORMDL3, OXA1L, OGFRL1 | PTGIR 1125/4885PTGDR 1527/4885SRD5A1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.